Document Detail


Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor.
MedLine Citation:
PMID:  21486221     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aryl hydrocarbon receptor (AhR) is a ligand activated basic helix-loop-helix transcription factor that binds to environmental poly aromatic hydrocarbons (PAH) and mediates their toxic and carcinogenic responses. There is ample documentation for the role of AhR in PAH-induced carcinogenicity. However, in this report we addressed whether overexpression of AhR alone is sufficient to induce carcinogenic transformation in human mammary epithelial cells (HMEC). Retroviral expression vectors were used to develop a series of stable cell lines expressing varying levels of AhR protein in an immortalized normal HMEC with relatively low endogenous AhR expression. The resulting increase in AhR expression and activity correlated with the development of cellular malignant phenotypes, most significantly epithelial-to-mesenchymal transition. Clones overexpressing AhR by more than 3-fold, exhibited a 50% decrease in population doubling time. Cell cycle analysis revealed that this increase in proliferation rates was due to an enhanced cell cycle progression by increasing the percentage of cells transiting into S- and G2/M phases. Cells overexpressing AhR exhibited enhanced motility and migration. Importantly, these cells acquired the ability to invade matrigel matrix, where more than 80% of plated cells invaded the matrigel matrix within 24 h, whereas none of parental or the vector control HMEC were able to invade matrigel. Collectively, these data provide evidence for a direct role of AhR in the progression of breast carcinoma. The results suggest a novel therapeutic target that could be considered for treatment and prevention of breast cancer progression.
Authors:
J Brooks; S E Eltom
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Current cancer drug targets     Volume:  11     ISSN:  1873-5576     ISO Abbreviation:  Curr Cancer Drug Targets     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-23     Completed Date:  2011-09-16     Revised Date:  2014-07-07    
Medline Journal Info:
Nlm Unique ID:  101094211     Medline TA:  Curr Cancer Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  654-69     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Basic Helix-Loop-Helix Transcription Factors / biosynthesis*,  genetics,  physiology
Breast Neoplasms / drug therapy,  pathology
Cell Cycle
Cell Cycle Proteins / metabolism
Cell Line
Cell Line, Tumor
Cell Movement
Cell Nucleus / metabolism
Cell Proliferation
Cell Transformation, Neoplastic / metabolism*,  pathology
Clone Cells
Cytosol / metabolism
Epithelial Cells / cytology,  metabolism,  pathology
Epithelial-Mesenchymal Transition
Female
Gene Expression*
Gene Transfer Techniques
Humans
Mammary Glands, Human / cytology,  metabolism*,  pathology
Molecular Targeted Therapy
Protein Transport
RNA, Messenger / metabolism
Receptors, Aryl Hydrocarbon / biosynthesis*,  genetics,  physiology
Grant Support
ID/Acronym/Agency:
CA91408-01/CA/NCI NIH HHS; G12 RR003032/RR/NCRR NIH HHS; RR03032 15/RR/NCRR NIH HHS; SC1 CA153326/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/AHR protein, human; 0/Basic Helix-Loop-Helix Transcription Factors; 0/Cell Cycle Proteins; 0/RNA, Messenger; 0/Receptors, Aryl Hydrocarbon
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A cross-talk between NFAT and NF-?B pathways is crucial for nickel-induced COX-2 expression in Beas-...
Next Document:  The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of A...